We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Metamark Genetics and Definiens Form Partnership to Develop Cancer Diagnostics

By LabMedica International staff writers
Posted on 07 Jul 2011
Print article
Metamark Genetics, Inc. (Cambridge, MA, USA) a privately held oncology molecular diagnostic company, and Definiens (Munich, Germany) a health image-intelligence company, announced a development and commercialization partnership. The partnership combines Metamark's proprietary multiplex protein detection platform with image analysis technology developed jointly with Definiens to deliver innovative prognostic and predictive assays for early-stage cancers.

"We see great synergy in combining Definiens' technology and expertise with Metamark's unique understanding of tumor heterogeneity and insight into the molecular drivers regulating tumor formation and aggression. We believe that this partnership will enable us to codevelop and implement unique and important image analysis tools," said Eric Devroe, PhD, vice president of business & strategy development for Metamark.

Metamark's quantitative diagnostic approach can identify small regions of molecularly aggressive cancer cells within an otherwise indolent tumor. The company is addressing the "heterogeneous" nature of tumors not only between one patient and the next, but also within an individual patient's tumor by developing a portfolio of prognostic and predictive assays.

Definiens has made major achievements in the field of biomarker development based on its robust and scalable image analysis framework enabling scientists and clinicians to extract rapidly comprehensive biomarker and morphology expression profiles and to identify a relevant subset of descriptors by correlating them against patient outcomes.

"The capability to provide detailed readouts from tissue analysis is opening up new gateways for developing diagnostic assays as we enter the age of personalized medicine. We believe the Definiens Developer XD and Tissue Studio software will enable Metamark to classify tumor heterogeneity of multiplexed tissue stains and derive prognostic and predictive assays," said Thomas Colarusso, vice president of sales & operations for Definiens.

Related Links:
Metamark Genetics, Inc.
Definiens

Gold Member
Hematology Analyzer
Swelab Lumi
Automated Blood Typing System
IH-500 NEXT
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA
New
Gold Member
Syphilis Screening Test
VDRL Antigen MR

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.